fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-07-26
Company: Cerenis Therapeutics (France)
Investors: French Strategic Investment Fund (FSI - Fonds Stratégique d’Investissement) Sofinnova Partners (France) HealthCap (Sweden) Alta Partners (France) TVM Capital (Germany) EDF Ventures (USA) OrbiMed (USA) DAIWA Corporate Investment (Japan)
Amount: € 40 million
Planned use: This third round of financing (Series C) for Cerenis will fund Phase II development of the lead Cerenis program, CER-001, an HDL-mimetic for the treatment of cardiovascular disease and to support the development of other new HDL therapies.
Other: Cerenis Therapeutics has raised €40 million in the first close of its series C financing. In this round €20 million came from the Fund for Strategic Investment (FSI) with an additional €20 million coming from the existing investors: Sofinnova Partners, HealthCap, Alta Partners and TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.
This round of financing brings the total capital raised to date by the company to €107 million.

Jean-Pierre Garnier, former CEO of GSK and Pierre Fabre Laboratories, will join the Cerenis Board of Directors as a Non-Executive Director. He will be FSI’s representative on the board.